Corporate ActionMay 20, 2026, 04:43 PM
Supernus to pay $33.4M milestone for CVR Agreement achievement
AI Summary
Supernus Pharmaceuticals announced it is obligated to pay approximately $33.4 million under its Contingent Value Right (CVR) Agreement. This obligation arose because Milestone 1, as defined in the CVR Agreement, was achieved on March 18, 2026. The company will pay $0.50 per CVR, with funds to be deposited with the Rights Agent within 20 business days of the May 17, 2026 notice date.
Key Highlights
- Supernus Pharmaceuticals is obligated to pay approximately $33.4 million.
- The payment is for the achievement of Milestone 1 under a Contingent Value Right (CVR) Agreement.
- Milestone 1 was achieved on March 18, 2026.
- The payment amount is $0.50 per Contingent Value Right.
- Funds will be deposited with the Rights Agent within 20 business days of the May 17, 2026 notice date.
Price Impact
More from SUPN